Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Сартаны в лечении больных артериальной гипертензией высокого риска: возможности кандесартана
Сартаны в лечении больных артериальной гипертензией высокого риска: возможности кандесартана
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В работе представлен обзор литературы по вопросам лечения артериальной гипертензии препаратами, блокирующими активность ренин-ангиотензин-альдостероновой системы, – блокаторами рецепторов ангиотензина II, действие которых основано на торможении активности ренин-ангиотензин-альдостероновой системы на уровне рецепторов ангиотензина II. Блокатор ангиотензиновых рецепторов кандесартан (Атаканд®) наряду с выраженным долгосрочным антигипертензивным действием обладает органопротективными свойствами (вызывает обратное развитие гипертрофии левого желудочка, оказывает нефропротекцию), антидиабетогенным действием, предупреждает развитие мозгового инсульта. Опыт клинического применения кандесартана свидетельствует о высокой эффективности и хорошем спектре безопасности у разных категорий больных артериальной гипертензией, при сочетанной патологии, при хронической сердечной недостаточности, сахарном диабете, ожирении.
Ключевые слова: артериальная гипертензия, антигипертензивная терапия, блокада ренин-ангиотензин-альдостероновой системы, блокатор рецепторов ангиотензина II, органопротекция, гипертрофия миокарда левого желудочка, кандесартан, Атаканд®.
Key words: hypertension, hypertension, antihypertensive therapy, blockade of the renin-angiotensin-aldosterone system, angiotensin receptor blocker II, organoprotective, regression of LVH, candesartan, Atakand®.
Ключевые слова: артериальная гипертензия, антигипертензивная терапия, блокада ренин-ангиотензин-альдостероновой системы, блокатор рецепторов ангиотензина II, органопротекция, гипертрофия миокарда левого желудочка, кандесартан, Атаканд®.
________________________________________________
Key words: hypertension, hypertension, antihypertensive therapy, blockade of the renin-angiotensin-aldosterone system, angiotensin receptor blocker II, organoprotective, regression of LVH, candesartan, Atakand®.
Полный текст
Список литературы
1. Ezzati M, Lopez A, Rodgers A et al. Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected Major Risk Factors. Geneva: World Health Organization, 2004.
2. Chobanian AV. Shattuck Lecture. The hypertension paradox – more uncontrolled disease despite improved therapy. N Engl J Med 2009; 361: 878–87.
3. Диагностика и лечение АГ. Рекомендации Российского медицинского общества по АГ и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика. 2010; 7 (6). Прил. 2.
4. Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462–536.
5. Haralambos P. Gavras, Salernob CM. The angiotensin II Type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18 (6): 1058–67.
6. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 18S–24S.
7. Edwards RM, Aiyar N, Ohlstein EH et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260: 175–81.
8. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S73–86.
9. Puig JG et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertension 1999; 17: 1033–9.
10. Wurzner C et al. Comparative effects of losartan and ibresartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertension 2001; 19: 1855–60.
11. Pitt B et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.
12. Granger CB, McMurray JJV et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
13. Brenner BM, Cooper ME, de Zeeuw D et al. The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). N Engl J Med 2001; 345: 861–9.
14. Julius S, Kjeldsen SE et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE. Lancet 2004; 363: 2022–31.
15. Vauquelin G, Fierens FLP, Verheijen I et al. Distinctions between non-peptide angiotensin II AT1-receptor antagonists. JRAAS 2001; 2 (Suppl. 1): S24–S31.
16. Unger T. Differences among angiotensin II type 1 receptor blockers: characterization of candesartan cilexetil. Blood Pressure 2000; 9 (Suppl. 1): 14–8.
17. Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil - possible mechanisms of long-term antihypertensive action. J Hum Hypertens 1999; 13 (Suppl. 1): S75–S80.
18. Hubner R, Hogemann AM, Sunzel M, Riddell JC. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S19–S25.
19. Unger T. Inhibiting renin-angiotensin in the brain: the possible therapeutic implications. Blood Pressure 2001; 10 (Suppl. 1): 12–6.
20. Van Lier JJ, van Heiningen PNM, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S27–S28.
21. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13 (Suppl. 1): S69–S73.
22. McInnes GT, O'Kane KPJ, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl. 1): S75–S80.
23. Belcher G, Hubner R, George M et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 13 (Suppl. 1): S85–S89.
24. Trenkwalder P. Efficacy and tolerability of candesartan cilexetil in special patients group. Blood Pressure 2000; 9 (Suppl. 1): 27–30.
25. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II, in comparison with losartan. Blood Pressure 1998; 7 (1): 53–9.
26. Bakris GL, Gilles TD, Weber MA. Clinical efficacy and safety profiles of AT1-receptor antagonists. Cardiovascul Rev Reports 1999; 20 (2): 1–19.
27. Bakris G, Grandma Reef M et al. Antihypertensive efficacy of candesartan in comparison to losartan: The CLAIM study. J Clin Hypertens 1001; 3: 16–21.
28. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II receptor antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1999; 13 (Suppl. 1): S49–S57.
29. Hennersdorf MG, Strauer BE. Arterial hypertension and cardiac arrhythmias. J Hypertens 2001; 19: 167–77.
30. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41–6.
31. Spratt J, Shiels A, Williams B et al. On behalf of the LVH study group. Effects of candesartan cilexetil on left ventricular and arterial structure and function in hypertensive patients. J Hypertens 2000; 18 (Suppl. 2): S188.
32. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.
33. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatmen and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563–74.
34. Lithell H, Hansson L, Elmfeldt D et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J Hypertens 2003; 21: 875–86.
35. Pfeffer MF, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: CHARM-overall program. Lancet 2003; 362: 759–66.
36. Yusuf S, Ostergren JB, Gerstein HC et al. Effect of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48–53.
37. Burgess E. Renal effects of angiotensin II receptor antagonists. Blood Pressure 2000; 10 (Suppl. 1): 17–20.
38. Morgensen E, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440–4.
39. Андрущишина Т.Б., Морозова Т.Е. Интенсивный контроль артериального давления: возможности комбинированной фармакотерапии. Системные гипертензии. 2009; 2: 22–7.
40. Морозова Т.Е., Юдина И.Ю. Современная стратегия улучшения приверженности лечению больных артериальной гипертонией: фиксированные комбинации лекарственных средств. Cons. Med. 2010; 1: 22–8.
2. Chobanian AV. Shattuck Lecture. The hypertension paradox – more uncontrolled disease despite improved therapy. N Engl J Med 2009; 361: 878–87.
3. Диагностика и лечение АГ. Рекомендации Российского медицинского общества по АГ и Всероссийского научного общества кардиологов. Кардиоваскулярная терапия и профилактика. 2010; 7 (6). Прил. 2.
4. Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462–536.
5. Haralambos P. Gavras, Salernob CM. The angiotensin II Type 1 receptor blocker losartan in clinical practice: a review. Clin Ther 1996; 18 (6): 1058–67.
6. Oparil S. Newly emerging pharmacologic differences in angiotensin II receptor blockers. Am J Hypertens 2000; 13 (1 Pt 2): 18S–24S.
7. Edwards RM, Aiyar N, Ohlstein EH et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J Pharmacol Exp Ther 1992; 260: 175–81.
8. Israili ZH. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. J Hum Hypertens 2000; 14 (Suppl. 1): S73–86.
9. Puig JG et al. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertension 1999; 17: 1033–9.
10. Wurzner C et al. Comparative effects of losartan and ibresartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertension 2001; 19: 1855–60.
11. Pitt B et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–52.
12. Granger CB, McMurray JJV et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003; 362: 772–6.
13. Brenner BM, Cooper ME, de Zeeuw D et al. The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). N Engl J Med 2001; 345: 861–9.
14. Julius S, Kjeldsen SE et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE. Lancet 2004; 363: 2022–31.
15. Vauquelin G, Fierens FLP, Verheijen I et al. Distinctions between non-peptide angiotensin II AT1-receptor antagonists. JRAAS 2001; 2 (Suppl. 1): S24–S31.
16. Unger T. Differences among angiotensin II type 1 receptor blockers: characterization of candesartan cilexetil. Blood Pressure 2000; 9 (Suppl. 1): 14–8.
17. Inada Y, Ojima M, Kanagawa R et al. Pharmacologic properties of candesartan cilexetil - possible mechanisms of long-term antihypertensive action. J Hum Hypertens 1999; 13 (Suppl. 1): S75–S80.
18. Hubner R, Hogemann AM, Sunzel M, Riddell JC. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S19–S25.
19. Unger T. Inhibiting renin-angiotensin in the brain: the possible therapeutic implications. Blood Pressure 2001; 10 (Suppl. 1): 12–6.
20. Van Lier JJ, van Heiningen PNM, Sunzel M. Absorption, metabolism and excretion of 14C-candesartan and 14C-candesartan cilexetil in healthy volunteers. J Hum Hypertens 1997; 11 (Suppl. 2): S27–S28.
21. Sever P, Holzgreve H. Long-term efficacy and tolerability of candesartan cilexetil and losartan in patients with mild to moderate hypertension. J Hum Hypertens 1999; 13 (Suppl. 1): S69–S73.
22. McInnes GT, O'Kane KPJ, Jonker J, Roth J. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens 1997; 11 (Suppl. 1): S75–S80.
23. Belcher G, Hubner R, George M et al. Candesartan cilexetil: safety and tolerability in healthy volunteers and patients with hypertension. J Hum Hypertens 1997; 13 (Suppl. 1): S85–S89.
24. Trenkwalder P. Efficacy and tolerability of candesartan cilexetil in special patients group. Blood Pressure 2000; 9 (Suppl. 1): 27–30.
25. Andersson OK, Neldam S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II, in comparison with losartan. Blood Pressure 1998; 7 (1): 53–9.
26. Bakris GL, Gilles TD, Weber MA. Clinical efficacy and safety profiles of AT1-receptor antagonists. Cardiovascul Rev Reports 1999; 20 (2): 1–19.
27. Bakris G, Grandma Reef M et al. Antihypertensive efficacy of candesartan in comparison to losartan: The CLAIM study. J Clin Hypertens 1001; 3: 16–21.
28. Elmfeldt D, George M, Hubner R, Olofsson B. Candesartan cilexetil, a new generation angiotensin II receptor antagonist, provides dose dependent antihypertensive effect. J Hum Hypertens 1999; 13 (Suppl. 1): S49–S57.
29. Hennersdorf MG, Strauer BE. Arterial hypertension and cardiac arrhythmias. J Hypertens 2001; 19: 167–77.
30. Klingbeil AU, Schneider M, Martus P et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41–6.
31. Spratt J, Shiels A, Williams B et al. On behalf of the LVH study group. Effects of candesartan cilexetil on left ventricular and arterial structure and function in hypertensive patients. J Hypertens 2000; 18 (Suppl. 2): S188.
32. Cuspidi C, Muiesan ML, Valagussa L et al. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the Candesartan Assessment in the Treatment of Cardiac Hypertrophy (CATCH) study. J Hypertens 2002; 20: 2293–300.
33. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive treatmen and Lipid Profile In a North of Sweden efficacy Evaluation (ALPINE) study. J Hypertens 2003; 21: 1563–74.
34. Lithell H, Hansson L, Elmfeldt D et al. The Study of Cognition and Prognosis in the Elderly (SCOPE). J Hypertens 2003; 21: 875–86.
35. Pfeffer MF, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: CHARM-overall program. Lancet 2003; 362: 759–66.
36. Yusuf S, Ostergren JB, Gerstein HC et al. Effect of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. Circulation 2005; 112: 48–53.
37. Burgess E. Renal effects of angiotensin II receptor antagonists. Blood Pressure 2000; 10 (Suppl. 1): 17–20.
38. Morgensen E, Neldam S, Tikkanen I et al. Randomised controlled trial of dual blockade renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Brit Med J 2000; 321: 1440–4.
39. Андрущишина Т.Б., Морозова Т.Е. Интенсивный контроль артериального давления: возможности комбинированной фармакотерапии. Системные гипертензии. 2009; 2: 22–7.
40. Морозова Т.Е., Юдина И.Ю. Современная стратегия улучшения приверженности лечению больных артериальной гипертонией: фиксированные комбинации лекарственных средств. Cons. Med. 2010; 1: 22–8.
Авторы
Т.Е.Морозова
ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
temorozova@gmail.com
temorozova@gmail.com
ФППОВ ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
temorozova@gmail.com
________________________________________________
temorozova@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.